Page 10 - Hennigsdorf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hennigsdorf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hennigsdorf Today - Breaking & Trending Today

SphingoTec GmbH: Boditech Med and SphingoTec Close Global Licensing Agreement for Kidney Function Biomarker Proenkephalin A 119-159

Worldwide licensing agreement signed to develop and offer penKid as test on Boditech's fully automated immunoassay systems.The biomarker penKid adds diagnostic value and addresses current unmet needs in ....

Kangwon Do , South Korea , Republic Of Korea , Kostenloser Wertpapierhandel , Sphingotec Gmbh , Sphingotec Gmbhview , Eui Yul Choi , Sphingotec Gmb , Ruxandra Lenz , Boditech Med Inc , Clin Chem Lab , Boditech Med , Yul Choi , Early Biomarker , Septic Acute Kidney Injury , Septic Shock , Chem Lab , New Biomarker , Pediatric Acute Kidney Injury , Children Under One Year , Tec Gmbh ,

DB to work with Siemens and Alstom on next generation of high-speed trains

DB is looking ahead to design its high-speed train fleet for the 2030s by appointing Siemens and Alstom to develop concepts. ....

Saint Ouen , Poitou Charentes , Albrecht Neumann , Siemens Mobility , French Railways ,

Munich neighbours sue to block construction of 'noisy' Kita

Munich neighbours sue to block construction of 'noisy' Kita
thelocal.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelocal.de Daily Mail and Mail on Sunday newspapers.

Baden Wüberg , Nordrhein Westfalen , Friso Gentsch , William Kane , Riaan Kritzinger , Fiona Boyd , How Germany ,

Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming

/PRNewswire/ Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D.,. ....

Kenji Yasukawa , Klaus Giese , Taiji Sawamoto , Brandenburg Innovationsforum , Astellas Pharma Inc , Research Operations , Drug Development , Astellas Pharma , Pantherna Therapeutics Gmbh , Chief Executive Officer , Executive Vice President , Applied Research , Focus Area , Focus Area Approach , Trend Honor , Innovative Product , Leap Innovations Nucleic , Astellas Pharma Inc ,

Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming

/PRNewswire/ Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D.,. ....

Kenji Yasukawa , Klaus Giese , Taiji Sawamoto , Brandenburg Innovationsforum , Astellas Pharma Inc , Research Operations , Drug Development , Astellas Pharma , Pantherna Therapeutics Gmbh , Chief Executive Officer , Executive Vice President , Applied Research , Focus Area , Focus Area Approach , Trend Honor , Innovative Product , Leap Innovations Nucleic , Astellas Pharma Inc ,